|
|
||||||||
From the Department of Neurology, EMG/ENG Laboratory (A.A.A., E.C., P.P.) and Department of Medicine, Division of Oncology (G.I., A.K., T.M., M.K.G., P.G., K.A., H.P.K.), University of Patras Medical School, Rion-Patras, Greece.
Address correspondence and reprint requests to Dr. Andreas A. Argyriou, Neurology Department, EMG/ENG Laboratory, University of Patras Medical School, 26504, Rion-Patras, Greece; e-mail: andargyriou{at}yahoo.gr
We conducted a randomized, open-label, controlled trial to assess the efficacy of oxcarbazepine for prophylaxis against oxaliplatin-induced peripheral neuropathy (OxIN). Thirty-two patients with colon cancer received 12 courses of the FOLFOX-4 regimen and were randomly assigned to receive oxcarbazepine (600 mg BID) or chemotherapy without oxcarbazepine. The incidence of OxIN was strikingly decreased in patients receiving oxcarbazepine (31.2% vs 75%). Oxcarbazepine may prevent OxIN symptoms. Further larger placebo-controlled trials are warranted to confirm our results.
Disclosure: The authors report no conflicts of interest.
Received June 15, 2006. Accepted in final form September 15, 2006.
Related Article
Neurology 2006 67: 2102-2103.
This article has been cited by other articles:
![]() |
A. A. Argyriou, P. Polychronopoulos, and E. Chroni The Usefulness of Nerve Conduction Studies in Objectively Assessing Oxaliplatin-Induced Peripheral Neuropathy Oncologist, November 1, 2007; 12(11): 1371 - 1372. [Full Text] [PDF] |
||||
![]() |
W.-S. Wang, J.-K. Lin, T.-C. Lin, W.-S. Chen, J.-K. Jiang, H.-S. Wang, T.-J. Chiou, J.-H. Liu, C.-C. Yen, and P.-M. Chen In Reply Oncologist, November 1, 2007; 12(11): 1372 - 1373. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |